Cited 0 times in Scipus Cited Count

Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors.

DC Field Value Language
dc.contributor.authorHanes, J-
dc.contributor.authorSills, A-
dc.contributor.authorZhao, Z-
dc.contributor.authorSuh, KW-
dc.contributor.authorTyler, B-
dc.contributor.authorDiMeco, F-
dc.contributor.authorBrat, DJ-
dc.contributor.authorChoti, MA-
dc.contributor.authorLeong, KW-
dc.contributor.authorPardoll, DM-
dc.contributor.authorBrem, H-
dc.date.accessioned2011-08-22T05:18:40Z-
dc.date.available2011-08-22T05:18:40Z-
dc.date.issued2001-
dc.identifier.issn0724-8741-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/3877-
dc.description.abstractPURPOSE: The purpose of our study was to develop an injectable polymeric system for the long-term localized delivery of bioactive interleukin-2 for antitumor immunotherapy.



METHODS: IL-2 was encapsulated into gelatin and chondroitin-6-sulfate using an aqueous-based complex coacervation. CTLL-2 cells were used to measure the bioactivity of released IL-2 and radiolabeled IL-2 was used for release studies in the rat brain and mouse liver. Antitumor efficacy studies were carried out in primary (9L gliosarcoma) and metastatic (B16-F10 melanoma) brain tumor models in rats and mice, respectively, as well as a murine liver tumor model (CT26 carcinoma). Survivors of the metastatic brain tumor challenge were rechallenged with tumor in the opposite lobe of the brain to confirm that antitumor immunologic memory had developed.



RESULTS: Bioactive IL-2 was released for over 2 weeks in vitro and in vivo IL-2 release showed significant IL-2 levels for up to 21 days. Polymeric IL-2 microspheres injected intratumorally were statistically more effective in protecting animals challenged with fatal tumor doses in the brain and the liver than placebo or autologous tumor cells genetically engineered to secrete IL-2. Immunologic memory was induced following IL-2 microsphere therapy in the B16-F10 brain tumor model that was capable of protecting 42% of animals from a subsequent intracranial tumor challenge, suggesting that tumor destruction was mediated by the immune system.



CONCLUSIONS: Local IL-2 therapy using novel polymeric carriers. aimed at stimulating long-lasting antitumor immunity, may provide an improved method of treating a variety of cancers.
-
dc.language.isoen-
dc.subject.MESHAnimals-
dc.subject.MESHAntineoplastic Agents-
dc.subject.MESHBiocompatible Materials-
dc.subject.MESHBrain-
dc.subject.MESHBrain Neoplasms-
dc.subject.MESHDrug Delivery Systems-
dc.subject.MESHInterleukin-2-
dc.subject.MESHLiver Neoplasms, Experimental-
dc.subject.MESHMelanoma, Experimental-
dc.subject.MESHMice-
dc.subject.MESHMice, Inbred BALB C-
dc.subject.MESHMice, Inbred C57BL-
dc.subject.MESHMicrospheres-
dc.subject.MESHPolymers-
dc.subject.MESHRats-
dc.subject.MESHRats, Inbred F344-
dc.subject.MESHTumor Cells, Cultured-
dc.titleControlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors.-
dc.typeArticle-
dc.identifier.pmid11496947-
dc.identifier.urlhttp://www.kluweronline.com/art.pdf?issn=0724-8741&volume=18&page=899-
dc.contributor.affiliatedAuthor서, 광욱-
dc.type.localJournal Papers-
dc.citation.titlePharmaceutical research-
dc.citation.volume18-
dc.citation.number7-
dc.citation.date2001-
dc.citation.startPage899-
dc.citation.endPage906-
dc.identifier.bibliographicCitationPharmaceutical research, 18(7). : 899-906, 2001-
dc.identifier.eissn1573-904X-
dc.relation.journalidJ007248741-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse